Our most effective dose of EGCG was similar to that found by Kang et al. who showed that approximately 20–40 μM EGCG inhibited α-SMA and collagen type I production in nasal polyp-derived fibroblasts [50] and to another study which found that 40 μM EGCG largely obliterated fibronectin production in primary dermal fibroblasts [51]. The gene discussed is ACTA1; the disease is nasal cavity polyp.